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Introduction
GBS is an acute demyelinating disease of peripheral nerves, which 
usually follows viral or bacterial illness. There is considerable evidence 
that GBS is an immune-mediated disease often due to a gastrointestinal 
or, more rarely, to a lung infection [1]. However, the exact pathogenesis 
remains unclear. In this case report, we describe a patient in which 
a preceding lung infection, associated with a co-administration of 
simvastatin and clarithromycin, resulting in rhabdomyolysis and acute 
inflammatory demyelinating polineuropathy.
Case Report
An 81-year-old Caucasian man presented to the emergency 
department complaining of dyspnea, chest and abdominal pain and 
severe and progressive weakness for the last 30 days. 
His medical history was significant for hypertension, BPCO, 
diabetes type 2, gout, mild renal failure, heart failure after myocardial 
infarction (ejection fraction 54%) and coronary heart disease. Two 
weeks before admission in our department, the same patient had 
been admitted to for dyspnoea, chest pain and elevated temperature. 
This clinical condition has due to pneumonia, and was treated with 
clarithromycin 500 mg twice a day. He had been taking, among other 
drugs, simvastatin 20mg/once/day for almost one year before.
The patient, after 14 days of discharge returned to the hospital, 
with classical signs of rhabdomyolisis. Laboratory chemistry revealed 
a significant elevation of CK (maximum dosage detected 3956 U/l; 
normal range 60-190 UI/l), myoglobin (maximum 5049 ng/ml; normal 
range ≤ 90 ng/ml) and myoglobinuria (maximum 1010 mg/L; normal 
range  4 mg/L); also GPT-ALT (maximum 142 UI/l; normal range 
9-63 UI/l), GOT-AST (maximum 77 U/l; normal range 13-41 UI/L) 
and GGT (maximum 175U/l; normal value ≤ 55U/L) levels were 
raised. Neurological examination showed a moderate tetraparesis, 
muscles very painful to pressure, and tendon reflexes unremarkable in 
the upper extremities; instead, in the legs, tendon reflexes could not 
be elicited. Needle electromiography (EMG) did not reveal a typical 
myopathic pattern, but during the routine F-wave evaluation we 
recorded the presence of A-wave. The electroneurography displayed 
a motor-sensitive predominantly axonal poliradicoloneuropathy. The 
examination of cerebro-spinal fluid (CSF) showed a moderate damage 
of emotion-encephalic barrier with an albumin-citologic dissociation 
and systemic production of 6 oligoclonal immunoglobulins. The 
simvastatin was stopped and treatment with forced urine alkalization 
was started. A diagnosis of GBS syndrome was made and the patient 
was started intravenous immunoglobulins therapy with prompt 
improvement: the paresis improved and the serum CK and myoglobin 
dropped to normal levels (<159U/l and <85 ng/ml respectively).
Discussion
Usually‚ one-half to two-third of GBS patients report antecedent 
infections, and Campylobacter jejuni, Cytomegalovirus (CMV), 
Epstein-Barr virus (EBV) and Mycoplasma pneumonia are recognised 
triggering agents of GBS [2]. Moreover, Micoplasma Pneumoniae 
infection appears to be associated strongly with GBS cases (15%) 
[3]. Moreover, marked raised levels of CK has been recognized and 
documented in GBS, correlating with occurrence of pain, [4] which was 
a presenting symptom in this patient. Raised level of CK can be a feature 
of the early course of GBS, and may cause diagnostic confusion with 
other conditions, particularly if the clinical picture is not typical. In fact, 
rhabdomyolysis is also a rare side-effect of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMGA-CoA) reductase inhibitors. Co-medication with 
inhibitors of the CYP34A pathway-as Clarithromycin– may increase 
this risk of rhabdomyolysis [5]. In our case, the patient, 3 weeks before 
Abstract
Guillan-Barré Syndrome (GBS) is an acute, symmetrical polyneuropathy with a clinical manifestation of flaccid 
paralysis with areflexia and variable sensory disturbance. GBS has an incidence of 1-2 cases/100.000 inhabitants 
for year. The pathological spectrum of GBS includes Acute Inflammatory Demyelinating Polyneuropathy (AIDP), 
Acute Motor Axonal Neuropathy (AMAN) and Acute Motor Sensory Axonal Neuropathy (AMSAN). We report a case 
of an 81-year-old man with GBS (subtype AMSAN), secondary to a previous Micoplasma Pneumoniae infection, who 
presented with an elevation of Creatin Kinase (CK) serum levels, and worsened by a co-administration of statins 
and clarithromycin. By our knowledge there are few cases in the literature in which the association of these drugs 
contributed to worsening GBS.
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the first admission to the hospital, had presented dyspnea and chest 
pain, so atypical pneumonia was suspected and diagnosis of pneumonia 
was made based with clinical and instrumental texts (including chest 
X-ray (Figure 1), High Resolution Computer Tomography (HRCT) 
(Figure 2), tracheo-bronchial endoscopy with bronchial aspirated for 
cytologic and bacteriological examination). In addition, our patient 
started having symptoms of increased fatigue, shortness of breath, 
progressive and severe diffuse myalgia, cramps, exercise intolerance 
weakness, functional disability (inability to raise arms and legs) with 
the beginning of clarithromycin therapy. Clarithromycin, has been 
implicated in other many reports of statin-induced rhabdomyolysis 
[6,7] but was used only after signs and symptoms had developed. In 
the literature several reports show an important rhabdomyolysis 
following the co-administration of statins and macrolide antibiotics 
(such as clarithromycin or erythromycin), or other drugs that inhibit 
the cytochrome CYP3A4 pathway, but most of patients described in 
these studies were treated with high doses of statins (i.e. simvastatin 
80 mg/die). Our case demonstrates that even low-dose therapy 
with statins may result in severe side effects‚ when combined with 
CYP3A4-inhibiting drugs, especially in patients with kidney failure. 
Moreover, the previous pneumoniae could be triggering the GBS that 
was exacerbated by the use of dangerous concurrent medication with 
simvastatin and clarithromycin. In fact, the electromiographic pattern 
as considered the presence of rhabdomyolysis, but it was consistent 
with an AMSAN. The EMG in fact showed a nerve damage with a 
widespread denervation activity in progress on both left and right tibial 
anterior muscles, on the right side of the diaphragm and on the I first 
dorsal interosseous, suggestive of a motor-sensitive predominantly 
axonal poliradicoloneuropathy (Figure 3). 
In addition to neurophysiological examinations‚ that confirm this 
clinical picture‚ we have the result of CSF’s analysis. From a simple 
point of view, a sudden muscle denervation could account for release of 
muscle enzymes in acute axonal poliradiculoneuropathies, up to seven 
times of the upper limit of normal; however, in a previous report Scott 
and colleagues [8] highlighted a relative sparing of small autonomic 
fibres in early phases of illness in a patient presenting with acute 
rhabdomyolysis and later developing an atypical Guillain-Barrè axonal 
neuropathy. That makes unlikely an elevation of muscle enzymes as 
epiphenomena of severe denervation in progress.
Conclusion
In conclusion, by our knowledge, this is the first case in which 
GBS‚ due to a preceding lung infection‚ was strongly exacerbated by 
a severe rhabdomyiolysis for a co-administration of simvastatin at low 
dose, and clarithromycin. Moreover, our case shows how is important 
to evaluate the use of statins in association with others CYP3A4 
(Cytochrome P450 3A4) inhibiting drugs, particularly in patients with 
prior infective conditions, renal insufficiency or other risk factors such 
as diabetes, heart failure, age>80 years. It is crucial, in particular among 
physicians, to have an awareness of the interaction’s risk associated 
with these conditions because the early diagnosis and aggressive 
therapy may reduce the comorbidity and mortality and could result 
in rapid improvement, as shown in the present patient. In particular it 
is important to make an early diagnosis, through the use of laboratory 
tests and neurophysiological tests, and it’s also important to know the 
medical history of the patient and his treatment history to suspend or 
avoid, in case of suspected rhabdomyolysis, any dangerous associations. 
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Figure 1: Chest X-ray. Consolidation in the right emithorax and interstitial 
spread thickening.
Figure 2: High Resolution Computer Tomography (HRCT). Inflammatory-
flogistic finding. Note the thickening of bronchial walls, the signs of phlegmatic 
infarction and soft mass with nodular and ramified morphaology.
Figure 3: A-waves records. Set of A-waves recorded in our case of acute 
form of plyradiculoneuropathy.
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